AUSTIN, TX—Transarterial Y-90 radioembolization with resin microspheres using MIRD dosimetry for intrahepatic cholangiocarcinoma appears to be safe and shows promising survival outcomes, researchers from Beth Israel Deaconess Medical Center reported in an abstract presented at SIR. “There is this… Read More
AUSTIN, TX—Patients with metastatic neuroendocrine tumors may potentially be able to consider same-day mapping or no mapping prior to treatment with Y-90 radioembolization, based on the rare incidence of hepatopulmonary shunting in this population. Researchers presented their data in an abstract… Read More
AUSTIN, TX—A systemic review and meta-analysis has found that an average tumor dose of 275 Gy for patients with hepatocellular carcinoma (HCC) treated with Y-90 radioembolization is able to predict objective tumor response. The authors undertook the review and analysis to better understand Y-90… Read More
Radiation lobectomy is an evolving technique that offers an alternative to portal vein embolization for patients who are not surgical candidates as a result of insufficient future liver remnant. In this interview, Robert Lewandowski, MD, an interventional radiologist and Director of Interventional… Read More
liver cancer
Radioembolization with yttrium-90 (Y-90) microspheres may be an effective second-line therapy for patients with liver metastases from pancreatic adenocarcinoma, according to a study published in the Journal of Vascular and Interventional Radiology. The retrospective study involved 33 patients with… Read More
Dan Brown, MD
Dan Brown, MD, shows case examples demonstrating timing of Y-90 therapy and personalizing therapy to the patient's biology.
Patients with hepatocellular carcinoma (HCC) and gross vascular invasion (GVI) may have improved overall survival (OS) after being treated with dual modality radiation with external beam radiation therapy (EBRT) and transarterial radioembolization (TARE). Researchers reported their findings in the… Read More
Transarterial radioembolization with yttrium-90 (TARE-Y90) may be worth considering as an adjunctive therapy for pediatric patients with unresectable hepatic malignancies, according to a study published in Pediatric Blood Cancer. “TARE-Y90 of unresectable primary liver malignancy is both… Read More
IV drips
Transarterial radioembolization with yttrium-90 (TARE-Y90) of unresectable primary liver malignancy demonstrates an anticancer effect and could be used as adjunctive therapy in pediatric patients with unresectable hepatic malignancies. A new study published in Pediatric Blood & Cancer found… Read More
LIver Cancer spot
A nomogram including 6 pre-Y90 radioembolization (RAE) parameters predicted overall survival (OS) post-RAE, according to a study published in Clinical Colorectal Cancer. A total of 103 patients with colorectal cancer liver metastases treated with RAE from September 15, 2009 to March 21, 2017 were… Read More